Sumitomo Pharma Co., Ltd.
DNPUF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $284 | $157 | $336 | $494 |
| - Cash | $23 | $29 | $143 | $203 |
| + Debt | $305 | $428 | $335 | $269 |
| Enterprise Value | $566 | $555 | $528 | $560 |
| Revenue | $399 | $315 | $556 | $560 |
| % Growth | 26.8% | -43.4% | -0.8% | – |
| Gross Profit | $245 | $188 | $377 | $403 |
| % Margin | 61.5% | 59.8% | 67.8% | 71.9% |
| EBITDA | $39 | -$317 | -$3 | $98 |
| % Margin | 9.7% | -100.9% | -0.6% | 17.6% |
| Net Income | $24 | -$315 | -$75 | $56 |
| % Margin | 5.9% | -100.1% | -13.4% | 10.1% |
| EPS Diluted | 59.49 | -792.79 | -187.55 | 141.99 |
| % Growth | 107.5% | -322.7% | -232.1% | – |
| Operating Cash Flow | $17 | -$242 | $12 | $31 |
| Capital Expenditures | -$13 | -$16 | -$13 | -$13 |
| Free Cash Flow | $3 | -$258 | -$1 | $18 |